Table 1.

Summary of completed and ongoing clinical trials with mTOR inhibitors in liver cancer^*

	NCT No.	Status	Drug	Patient(s)		Gen.	Phase	HCC/ iCCA	Start	Completed	Result
Single agent for advanced liver cancer	NCT00390195	Completed	Everolimus	39	1		1/2	HCC	2006	2011	(43)
	NCT00321594	Completed	Temsirolimus	54	1		1/2	HCC	2006	2012	(44)
	NCT00516165	Completed	Everolimus	28	1		1/2	HCC	2007	2011
	NCT00973713	Completed	Everolimus	27	1		2	iCCA	2009	2012	(48)
	NCT01251458	Completed	Temsirolimus	46	1		1/2	HCC	2009	2016
	NCT01035229	Completed	Everolimus	546	1		3	HCC	2010	2013	(45)
	NCT01567930	Completed	Temsirolimus	26	1		2	HCC	2010	2013	(49)
	NCT00999882	Completed	AZD8055	26	2		1	HCC	2009	2011
	NCT01177397	Completed	CC223	173	2		1/2	HCC	2010	2016
Adjuvant combination therapy for advanced liver cancer	NCT01010126	Completed	Temsirolimus + Bevacizumab	28	1		2	HCC	2009	2017	(50)
	NCT02145559	Completed	Sirolimus + Metformin	24	1		1	HCC/ iCCA	2014	2018	(51)
	NCT00467194	Completed	Sirolimus + Bevacizumab	27	1		1	HCC	2006	2011	(52)
	NCT00775073	Completed	Everolimus + Bevacizumab	33	1		2	HCC	2008	2012
	NCT01687673	Completed	Temsirolimus + Sorafenib	28	1		2	HCC	2012	2019
	NCT01008917	Completed	Temsirolimus + Sorafenib	25	1		1	HCC	2009	2013	(53)
	NCT01005199	Completed	Everolimus + Sorafenib	106	1		2	HCC	2009	2016	(54)
	NCT01183663	Completed	Temsirolimus + Lenalidomide	2	1		1	HCC	2010	2016	(55)
	NCT01488487	Completed	Everolimus + Pasireotide	24	1		2	HCC	2011	2015
	NCT02724332	Completed	Sirolimus + TACE	300	1		1	HCC	2012	2015
	NCT01522820	Completed	Sirolimus + Tumor Vaccine	18	1		1	HCC	2012	2016
	NCT00949949	Completed	Everolimus + Gemcitabine + Cisplatin	38	1		1	iCCA	2009	2014
	NCT01888302	Completed	Everolimus + Gemcitabine + Cisplatin	1	1		1	iCCA	2013	2016
Adjuvant combination therapy after LTx	NCT00328770	Completed	Sirolimus + Immunosuppression reagents	70	1		2/3	HCC	1996	2006
	NCT00355862	Completed	Sirolimus+CNI/MMF/Steroids	525	1		3	HCC	2006	2014	(46)
	NCT01374750	Completed	Sirolimus compare Tacrolimus or Cyclosporine	45	1		2	HCC	2010	2016
	NCT02081755	Recruiting	Everolimus and Tacrolimus VS. Tacrolimus and Myfortic or CellCept Imuran	336	1		4	HCC	2014	2019
	NCT03500848	Not yet recruiting	Tacrolimus +Sirolimus+MMF and/or steroids	130	1		2/3	HCC	2018	2023

^*The completed and ongoing clinical trials (https://www.clinicaltrials.gov/) were included from their first start date until December 31, 2019. A search strategy was developed in combination with the Medical Subject Headings, Emtree and text terms, include ‘liver cancer’, ‘liver tumor’, ‘hepatocellular carcinoma’, ‘HCC’, ‘biliary cancer’, ‘cholangiocarcinoma’, ‘intrahepatic cholangiocarcinoma’, ‘ICC’, ‘iCCA’, ‘CCA’, ‘mammalian target of Rapamycin inhibitors’, ‘mTOR inhibitors’, ‘mTORi’, ‘Rapamycin’, ‘Rapamune’, ‘Sirolimus’, ‘Everolimus’, ‘RAD001’, ‘Deforolimus’, ‘AP23573’, ‘Temsirolimus’, ‘CCI-779’, ‘MLN0128’, ‘CC-233’, ‘NVP-BEZ235’, ‘AZD-8055’.